A PROSPECTIVE OBSERVATIONAL STUDY OF MANAGEMENT PROTOCOL OF LOCALLY ADVANCED CARCINOMA RECTUM AT MGMMC AND MY HOSPITAL, INDORE
- 21 May 2018
- journal article
- research article
- Published by Akshantala Enterprises Private Limited in Journal of Evolution of Medical and Dental Sciences
- Vol. 7 (21), 2628-2633
- https://doi.org/10.14260/jemds/2018/590
Abstract
BACKGROUND Before 1900, Colon and Rectal cancer incidence was negligible. Following economic development and industrialisation, the incidence of colorectal cancer has been rising dramatically. The vast majority (98%) of colon and rectal cancers comprises of Adenocarcinomas. Other rare rectal cancers included carcinoid (0.4%), lymphoma (1.3%) and sarcoma (0.3%). Squamous cell carcinomas may develop in the transition area from the rectum to the anal verge and are considered anal carcinomas. Very rare cases of squamous cell carcinoma of the rectum have been reported. Approximately, 20% of colon cancers develop in the cecum. MATERIALS AND METHODS This is a prospective study of all patients with locally advanced carcinoma rectum seen at MY and Cancer Hospital, Indore. Between January 2011 and October 2012, 45 patients with rectal cancer were seen at MY and Cancer Hospital, Indore. Their age range was 20 - 75 years. The male/female ratio was 1.3: 1. Fisher's exact test was applied for statistical analysis. RESULTS 15 had abdominoperineal (AP) resection, 10 had anterior resection and 20 had tumours that were not resectable. 9 of the 15 patients (60%) who had AP resection are alive till date, 6 died, while 10 out of the 10 who had anterior resection (100%) are alive till date. CONCLUSION Patients with advanced rectal cancer should receive postoperative chemoradiotherapy. Local control, distant spread and survival improves when postoperative radiation therapy is combined with chemotherapy.Keywords
This publication has 68 references indexed in Scilit:
- Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, non-inferiority trialThe Lancet Oncology, 2012
- Colorectal-Cancer Incidence and Mortality with Screening Flexible SigmoidoscopyThe New England Journal of Medicine, 2012
- Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trialsThe Lancet, 2012
- Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trialThe Lancet, 2012
- Outcomes Among Black Patients With Stage II and III Colon Cancer Receiving Chemotherapy: An Analysis of ACCENT Adjuvant TrialsJNCI Journal of the National Cancer Institute, 2011
- Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803JNCI Journal of the National Cancer Institute, 2011
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialThe Lancet, 2011
- Prediagnostic smoking history, alcohol consumption, and colorectal cancer survivalCancer, 2011
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME StudyJournal of Clinical Oncology, 2010
- Rectal CancerArchives of Surgery, 1998